

ACM BIOLABS ANNOUNCES NEW INVESTOR

Singapore, 17th May 2017 – ACM Biolabs announced today that it has secured funding from a strategic corporate investor.

Dr. Peter Moran, COO of ACM Biolabs, said “Although we are not at liberty to disclose the investor or funding amount, I can say that two things: First, the investor is a multinational company whose business interests align very well with ours and we are extremely happy to form a strong partnership with them. Second, this investment will allow us to significantly accelerate both our veterinary and human vaccine development, in continuation of our strategy of developing our internal pipeline in both areas.”

About ACM Biolabs Pte Ltd

ACM Biolabs is a synthetic biology company using its proprietary Artificial Cell Membrane (“ACM”) technology platform to allow its customers to develop diagnostics, therapeutics and vaccines targeting novel membrane proteins. ACM technology is being used by the world’s leading pharmaceutical companies to develop products requiring membrane proteins that are difficult or impossible to work with using traditional methods. ACM Biolabs has licensed technology from the Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector agency for science, research and development.

Media Contact: info@ACMBiolabs.com